A portable electronic nose can effectively detect precursors of oesophageal cancer, report researchers from the Radboud university medical center in the medical science journal GUT. This was demonstrated in an initial study involving more than four hundred patients. In time, this inexpensive and non-invasive technique may be used diagnostically to detect the precursor of oesophageal cancer (Barrett’s oesophagus) in general practice.
The number of cases of oesophageal cancer and its precursor - Barrett's oesophagus - has increased enormously in recent decades. The disease is usually diagnosed late and at an advanced stage, which makes treatment difficult. Barrett’s oesophagus is a pre-stage of oesophageal cancer, in which healthy, white-coloured cells at the base of the oesophagus have been replaced by aberrant, pink cells. The diagnosis of Barrett's oesophagus is done by using an endoscope with a camera that enters the oesophagus. An unpleasant and expensive procedure, which is poorly suited for population screening.
Researchers from Radboud university medical center, Bernhoven and CWZ therefore took a closer look at a less expensive and less cumbersome option. They investigated whether good diagnoses are possible with a portable electronic nose. An e-Nose, which measures volatile organic compounds (VOC) in exhaled air. These gaseous compounds are formed during all kinds of metabolic processes in the body. The idea is that changes in metabolism also lead to a different mix of these compounds. In this manner, you could measure inflammation through exhaled air, for instance, but also abnormal activities in the cells, thanks to the characteristic profiles that accompany them. The question is, how well could you smell Barrett’s oesophagus using such an e-Nose?
Of the more than 400 patients who participated in the study, 129 had Barrett's oesophagus and 141 had reflux (gastric acid returning to the oesophagus). 132 patients functioned as controls. Yonne Peters, Gastroenterologist researcher at Radboudumc: "After analysis, we saw markedly different exhalation profiles for these three groups. The sensitivity to detecting Barrett's oesophagus was high, namely 91 percent. This means that the test detects 91 out of 100 people with Barrett's oesophagus based on their exhalation profile. Selection of people who don't have Barrett's oesophagus - the specificity - is 74 percent."
"These figures are comparable to breast and colon cancer screening,” says gastroenterologist and research coordinator Peter Siersema. "After these encouraging results, further research among larger groups of people is obviously needed. If these results persist, its user-friendliness and low cost could contribute to making this breathalyser test interesting for non-invasive screening of Barrett's oesophagus by general practitioners."
Publication in GUT Detection of Barrett’s oesophagus through exhaled breath using an electronic nose device
Yonne Peters, Ruud W M Schrauwen, Adriaan C Tan, Sanne K Bogers, Bart de Jong, Peter D Siersema
Related news items
Frank Walboomers 25-years work anniversary at Radboudumc17 September 2020
Frank Walboomers, associate professor at the research group Regenerative Biomaterials at the Dept. of Dentistry (theme Reconstructive & Regenerative Medicine), celebrated his 25th work anniversary at Radboudumc.read more
Tjitske Kleefstra appointed endowed professor of Clinical genetics and psychopathology of rare syndromes17 September 2020
Tjitske Kleefstra has been appointed endowed professor of Clinical genetics and psychopathology of rare syndromes at the department of Neurodevelopmental disorders, with effect from 1 September.read more
Annette Schenck appointed professor of Translational Genetics17 September 2020
Annette Schenck has been appointed professor of Translational Genetics at the department of Neurodevelopmental disorders, with effect from 1 August. The chair will bring together fundamental and translational research in the field of brain developmental disorders.read more
Centuries-old medicine reduces the risk of new cardiovascular disease in heart patients17 September 2020
Colchicine, an anti-inflammatory drug that has been used for gout for centuries, has been shown to prevent cardiovascular disease in patients who have had a heart attack or are suffering from narrowed coronary arteries. Results of the study are published in the New England Journal of Medicine.read more
Radboudumc does large-scale research on systemic sclerosis10 September 2020
In rare diseases, such as systemic sclerosis, it’s often difficult to conduct large-scale research. Rheumatologist Madelon Vonk has managed to follow enough patients with systemic sclerosis for years. The results of her research have been published in BMJ Annal of the Rheumatic Diseases.read more